IL6 and breast cancer: Lapeire and colleagues demonstrated that OSM-neutralizing antibodies in combination with adipose tissue-derived CM treatment abolished the breast cancer malignant signatures and suggested that OSM is a more relevant factor in stimulation of breast cancer progression than other cytokines, such as IL-6 [52].